このエントリーをはてなブックマークに追加
ID 32881
JaLCDOI
FullText URL
Author
Murakami, Takanori
Ebara, Shin
Saika, Takashi
Irie, Shin
Takeda, Katsuji
Maki, Yoshio
Miyaji, Sadayuki
Manabe, Daisuke
Tsushima, Tomoyasu
Abstract

We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystoscopy and negative urinary cytology./

Keywords
bladder cancer
BCG therapy
transurethral biopsy
cystoscopy
urinary cytology
Amo Type
Original Article
Published Date
2007-12
Publication Title
Acta Medica Okayama
Volume
volume61
Issue
issue6
Publisher
Okayama University Medical School
Start Page
341
End Page
344
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID